Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
October 11, 2021

Coronavirus company news summary – India permits export of Russia’s Sputnik Light vaccine – Elixirgen signs global licensing deal for Covid-19 vaccine

By Darcy Jimenez

The Indian government has granted permission to Hetero Biopharma for the export of Russia’s Covid-19 vaccine, Sputnik Light. A vaccine production partner of the Russian Direct Investment Fund, Hetero Biopharma will export a total of four million doses of the vaccine to Russia, PTI reported. Sputnik Light is the first component of the Sputnik V Covid-19 vaccine and is not authorised for emergency usage in India.

Elixirgen Therapeutics has signed an exclusive licensing agreement with an undisclosed pharmaceutical firm for the rights to market its Covid-19 vaccine EXG-5003 internationally, except in Japan. The intradermal, temperature-controllable, self-replicating RNA vaccine expresses the SARS-CoV-2 spike protein’s receptor binding domain. It can elicit strong cellular immunity to offer wider protection against variants. The company is presently dosing subjects in a Phase I/II clinical trial of the vaccine in Japan.

Indian firms Aurobindo Pharma and MSN Laboratories have separately sought permission from the Central Drugs Standard Control Organisation’s Subject Expert Committee to conclude the late-stage clinical trials of Merck’s investigational oral antiviral therapy, molnupiravir, for the treatment of moderate Covid-19 patients. The move comes after Merck reported that the drug demonstrated favourable results in a trial involving subjects with mild-to-moderate disease.

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU